Adrian Cook

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Amit M. Oza, Adrian Cook, Jacobus Pfisterer et al. · The Lancet Oncology · 2015 · 845 citations · Full text

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

Christopher Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2020 · 386 citations · Full text

Urology, Radiation Medicine, Surgical Oncology +7

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Jonathan A. Ledermann, Andrew Embleton-Thirsk, Fharat Raja et al. · The Lancet · 2016 · 238 citations · Full text

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

Andrew R. Clamp, Elizabeth C James, Iain A. McNeish et al. · The Lancet · 2019 · 213 citations · Full text

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer

Alex Hoyle, Adnan Ali, Nicholas D. James et al. · European Urology · 2019 · 199 citations · Full text

Urology, Medicine, “ High- ” +4